Telbivudine.txt

CLINICAL USE

Treatment of chronic hepatitis B infection

DOSE IN NORMAL RENAL FUNCTION

600 mg daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :242.2

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :3.3

%Excreted unchanged in urine &nbsp &nbsp : 42

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :No data

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :30–53.6/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

30–50 600 mg every 48 hours<30 600 mg every 72 hours

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Dialysed. 600 mg every 96 hours

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. 600 mg every 96 hours

HDF/high flux &nbsp :Dialysed. 600 mg every 96 hours

CAV/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR<30 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Dosage guidelines are from the company and have not been tested so adjust the dose according to virological response and monitor for side effectsHas been associated with myopathy and myalgia4 hours of haemodialysis removes 23% of the dose.

Tags: post-by-auto-php